Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Days Inventory : 0.00 (As of Mar. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Regenerx Biopharmaceuticals Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Regenerx Biopharmaceuticals's Average Total Inventories for the three months ended in Mar. 2023 was $0.00 Mil. Regenerx Biopharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2023 was $0.00 Mil.

The historical rank and industry rank for Regenerx Biopharmaceuticals's Days Inventory or its related term are showing as below:

RGRX's Days Inventory is not ranked ^*
in the Biotechnology industry.
Industry Median: 191.36
* Ranked among companies with meaningful Days Inventory only.

Regenerx Biopharmaceuticals's Days Inventory stayed the same from Mar. 2022 (0.00) to Mar. 2023 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Regenerx Biopharmaceuticals's Inventory-to-Revenue for the three months ended in Mar. 2023 was 0.00.

Regenerx Biopharmaceuticals Days Inventory Historical Data

The historical data trend for Regenerx Biopharmaceuticals's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerx Biopharmaceuticals Days Inventory Chart

Regenerx Biopharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Inventory

Get a 7-Day Free Trial

Regenerx Biopharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Days Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Regenerx Biopharmaceuticals's Days Inventory

For the Biotechnology subindustry, Regenerx Biopharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenerx Biopharmaceuticals's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's Days Inventory distribution charts can be found below:

* The bar in red indicates where Regenerx Biopharmaceuticals's Days Inventory falls into.

Regenerx Biopharmaceuticals Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Regenerx Biopharmaceuticals's Days Inventory for the fiscal year that ended in Dec. 2022 is calculated as

	Days Inventory (A: Dec. 2022 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2021 )	+	Total Inventories (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Regenerx Biopharmaceuticals's Days Inventory for the quarter that ended in Mar. 2023 is calculated as:

	Days Inventory (Q: Mar. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Dec. 2022 )	+	Total Inventories (Q: Mar. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Regenerx Biopharmaceuticals (OTCPK:RGRX) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Regenerx Biopharmaceuticals's Inventory Turnover for the three months ended in Mar. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Regenerx Biopharmaceuticals's Inventory to Revenue for the three months ended in Mar. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0.019
	=	0.00

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Regenerx Biopharmaceuticals Days Inventory Related Terms

Thank you for viewing the detailed overview of Regenerx Biopharmaceuticals's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenerx Biopharmaceuticals Inc (OTCPK:RGRX) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850

Website

https://www.regenerx.com

Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.

Executives

Aptafin S P A	other: Member of 10% owner group	VIALE SHAKESPEARE 47, ROME L6 00144
Alessandro Noseda	director	C/O 15245 SHADY GROVE ROAD, SUITE 470, ROCKVILLE MD 20850
S.a. Sinaf	10 percent owner	26 BOULEVARD ROYAL, LUXEMBOURG N4 L-2449
Spa Essetifin	10 percent owner	VIA SUDAFRICA 20, ROME L6 00144
Francesca Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Preta Martina Cavazza	10 percent owner	VIA SUDAFRICA 20, ROME L6 00144
Mauro Bove	director	C/O REGENERX BIOPHARMACEUTICALS, INC., 3 BETHESDA METRO CENTER - SUITE 630, BETHESDA MD 20814
R Don Elsey	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
J J Finkelstein	director
Joseph C Mcnay	director	3 BETHESDA METRO CENTER STE 700, C/O REGENERX BIOPHARMACEUTICALS INC, BETHESDA MD 20814
Allan L Goldstein	director
Dane R Saglio	officer: Chief Financial Officer
Aria Digital	10 percent owner	22ND FL, PARKVIEW TOWER,, 248 JUNGJAIL-RO, BUNDANG-GU,, SEONGNAM-SI, GYEONGGI-DO M4 463-863